Sector ratings Alnylam Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 05/12/2025 GMT			5-day change	1st Jan Change
458.12 ^USD	-1.55%		+1.53%	+94.69%

12-03	Alnylam Pharmaceuticals Announces Changes to Board of Directors	CI
12-03	Alnylam Pharmaceuticals announces changes to board of directors	RE

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
ALNYLAM PHARMACEUTICALS, INC.	60.52B		AA	-
ELI LILLY AND COMPANY	905B		A
JOHNSON & JOHNSON	487B		BBB
ABBVIE INC.	400B		AA
ROCHE HOLDING AG	330B		AA
ASTRAZENECA PLC	281B		A
NOVARTIS AG	255B		AAA
MERCK & CO., INC.	248B		A
NOVO NORDISK A/S	214B		A
AMGEN INC.	178B		A
GILEAD SCIENCES, INC.	150B		AAA
PFIZER INC.	148B		BBB
SANOFI	120B		A
VERTEX PHARMACEUTICALS INCORPORATED	116B		AA
BRISTOL-MYERS SQUIBB COMPANY	106B		A
GSK PLC	96.52B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	87.18B		AA
ALLERGAN PLC	63.66B	-	-	-	-	-	-	-
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	57.93B		AA
TAKEDA PHARMACEUTICAL COMPANY LIMITED	44.82B		AA
Average	217.38B		AA
Weighted average by Cap.			AA